Visitors Now:
Total Visits:
Total Stories:
Profile image
Story Views

Now:
Last Hour:
Last 24 Hours:
Total:

Global Tetanus Drugs and Companies Pipeline Review H2 2016

Thursday, October 20, 2016 22:04
% of readers think this story is Fact. Add your two cents.

(Before It's News)

Summary

 ‘Tetanus – Pipeline Review, H2 2016’, provides an overview of the Tetanus pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Tetanus, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Tetanus and features dormant and discontinued projects.

Report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Request a sample report @ https://www.wiseguyreports.com/sample-request/693301-tetanus-pipeline-review-h2-2016

Scope

- The report provides a snapshot of the global therapeutic landscape of Tetanus
- The report reviews pipeline therapeutics for Tetanus by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Tetanus therapeutics and enlists all their major and minor projects
- The report assesses Tetanus therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Tetanus

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Tetanus
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Tetanus pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Complete report details @ https://www.wiseguyreports.com/reports/693301-tetanus-pipeline-review-h2-2016

 

Table of Contents
Table of Contents 2
List of Tables 7
List of Figures 8
Introduction 9
Report Coverage 9
Tetanus Overview 10
Therapeutics Development 11
Pipeline Products for Tetanus – Overview 11
Pipeline Products for Tetanus – Comparative Analysis 12
Tetanus – Therapeutics under Development by Companies 13
Tetanus – Therapeutics under Investigation by Universities/Institutes 15
Tetanus – Pipeline Products Glance 16
Late Stage Products 16
Clinical Stage Products 17
Early Stage Products 18
Tetanus – Products under Development by Companies 19
Tetanus – Products under Investigation by Universities/Institutes 21
Tetanus – Companies Involved in Therapeutics Development 22
Beijing Minhai Biotechnology Co., Ltd 22
Bharat Biotech International Limited 23
BioClonetics Immunotherapeutics, Inc. 24
Biological E. Limited 25
Boryung Pharmaceutical Co., Ltd. 26
Daiichi Sankyo Company, Limited 27
GlaxoSmithKline Plc 28
Green Cross Corporation 29
Indian Immunologicals Limited 30
Kaketsuken K.K. 31
LG Life Science LTD. 32
Panacea Biotec Limited 33
Prometheon Pharma, LLC 34
Sanofi Pasteur SA 35
Serum Institute of India Limited 36
Sinovac Biotech Ltd. 37
Zydus Cadila Healthcare Limited 38
Tetanus – Therapeutics Assessment 39
Assessment by Monotherapy Products 39
Assessment by Combination Products 40
Assessment by Target 41
Assessment by Route of Administration 43
Assessment by Molecule Type 45
Drug Profiles 47
(diphtheria + Haemophilus influenza [serotype B] + hepatitis B + pertussis (wholl cell) + tetanus) (pentavalent) vaccine – Drug Profile 47
Product Description 47
Mechanism Of Action 47
R&D Progress 47
(diphtheria + Haemophilus influenza [serotype B] + pertussis (acellular) + polio + tetanus) vaccine – Drug Profile 48
Product Description 48
Mechanism Of Action 48
R&D Progress 48
(diphtheria + haemophilus influenza [serotype B] + pertussis (acellular) + tetanus) vaccine – Drug Profile 49
Product Description 49
Mechanism Of Action 49
R&D Progress 49
(diphtheria + Haemophilus influenzae [serotype B] + hepatitis B + meningococcal [serotype C] + pertussis (whole cell) + poliomyelitis + tetanus) (7-valent) vaccine – Drug Profile 50
Product Description 50
Mechanism Of Action 50
R&D Progress 50
(diphtheria + Haemophilus influenzae [serotype B] + hepatitis B + pertussis (whole cell) + polio + tetanus) (hexavalent) vaccine – Drug Profile 51
Product Description 51
Mechanism Of Action 51
R&D Progress 51
(diphtheria + haemophilus influenzae [serotype B] + hepatitis B + pertussis (whole cell) + poliomyelitis + tetanus) (hexavalent) vaccine – Drug Profile 52
Product Description 52
Mechanism Of Action 52
R&D Progress 52
(diphtheria + Haemophilus influenzae [serotype B] + hepatitis B + pertussis (whole cell) + tetanus) (pentavalent) vaccine – Drug Profile 53
Product Description 53
Mechanism Of Action 53
R&D Progress 53
(diphtheria + haemophilus influenzae [serotype B] + hepatitis B + pertussis (whole cell) + tetanus) (pentavalent) vaccine – Drug Profile 54
Product Description 54
Mechanism Of Action 54
R&D Progress 54
(diphtheria + Haemophilus influenzae [serotype B] + pertussis (whole cell) + polio + tetanus)(pentavalent) vaccine – Drug Profile 55
Product Description 55
Mechanism Of Action 55
R&D Progress 55
(diphtheria + Haemophilus influenzae [serotype B] + pertussis (whole-cell) + tetanus) vaccine – Drug Profile 56
Product Description 56
Mechanism Of Action 56
R&D Progress 56
(diphtheria + pertussis (acellular) + poliovirus + tetanus) vaccine – Drug Profile 57
Product Description 57
Mechanism Of Action 57
R&D Progress 57
(diphtheria + pertussis (acellular) + tetanus) vaccine – Drug Profile 58
Product Description 58
Mechanism Of Action 58
R&D Progress 58
(diphtheria + pertussis (acellular) + tetanus) vaccine – Drug Profile 59
Product Description 59
Mechanism Of Action 59
R&D Progress 59
(diphtheria + pertussis (acellular) + tetanus) vaccine – Drug Profile 60
Product Description 60
Mechanism Of Action 60
R&D Progress 60
(diphtheria + pertussis (acellular) + tetanus) vaccine – Drug Profile 61
Product Description 61
Mechanism Of Action 61
R&D Progress 61
(diphtheria + pertussis (acellular) + tetanus) vaccine – Drug Profile 62
Product Description 62
Mechanism Of Action 62
R&D Progress 62
(diphtheria + pertussis (acellular) + tetanus) vaccine 1 – Drug Profile 63
Product Description 63
Mechanism Of Action 63
R&D Progress 63
(diphtheria + pertussis (acellular) + tetanus) vaccine 2 – Drug Profile 64
Product Description 64
Mechanism Of Action 64
R&D Progress 64
(diphtheria + pertussis (whole cell) + tetanus) vaccine – Drug Profile 65
Product Description 65
Mechanism Of Action 65
R&D Progress 65
(diphtheria + pertussis (whole-cell) + tetanus) vaccine – Drug Profile 66
Product Description 66
Mechanism Of Action 66
R&D Progress 66
(diphtheria + tetanus + pertussis (acellular) + hepatitis B + poliomyelitis [serotypes Mahoney + MEF-1 + Saukett] + haemophilus influenza [serotype B]) vaccine – Drug Profile 67
Product Description 67
Mechanism Of Action 67
R&D Progress 67
(diphtheria + tetanus + pertussis (acellular)) vaccine – Drug Profile 69
Product Description 69
Mechanism Of Action 69
R&D Progress 69
(diphtheria + tetanus) vaccine – Drug Profile 70
Product Description 70
Mechanism Of Action 70
R&D Progress 70
diphtheria + pertussis(acellular) + tetanus vaccine – Drug Profile 71
Product Description 71
Mechanism Of Action 71
R&D Progress 71
Eupenta – Drug Profile 72
Product Description 72
Mechanism Of Action 72
R&D Progress 72
GC-1107 – Drug Profile 73
Product Description 73
Mechanism Of Action 73
R&D Progress 73
GC-3111A – Drug Profile 74
Product Description 74
Mechanism Of Action 74
R&D Progress 74
KD-370 – Drug Profile 75
Product Description 75
Mechanism Of Action 75
R&D Progress 75
LBVD – Drug Profile 76
Product Description 76
Mechanism Of Action 76
R&D Progress 76
Monoclonal Antibody for Tetanus – Drug Profile 77
Product Description 77
Mechanism Of Action 77
R&D Progress 77
Monoclonal Antibody for Tetanus – Drug Profile 78
Product Description 78
Mechanism Of Action 78
R&D Progress 78
Monoclonal Antibody to Target Tetanus Toxin for Tetanus – Drug Profile 79
Product Description 79
Mechanism Of Action 79
R&D Progress 79
tetanus vaccine – Drug Profile 80
Product Description 80
Mechanism Of Action 80
R&D Progress 80
tetanus vaccine – Drug Profile 81
Product Description 81
Mechanism Of Action 81
R&D Progress 81
tetanus vaccine – Drug Profile 82
Product Description 82
Mechanism Of Action 82
R&D Progress 82
tetanus vaccine – Drug Profile 83
Product Description 83
Mechanism Of Action 83
R&D Progress 83
VN-0103 – Drug Profile 84
Product Description 84
Mechanism Of Action 84
R&D Progress 84
VN-0105 – Drug Profile 85
Product Description 85
Mechanism Of Action 85
R&D Progress 85
Tetanus – Dormant Projects 86
Tetanus – Discontinued Products 88
Tetanus – Product Development Milestones 89
Featured News & Press Releases 89
Apr 01, 2015: LG Life Sciences Succeeds in Phase 3 International Clinical Trials for 5-in-1 Vaccine Eupenta 89
Nov 24, 2014: CanSinotech submitted CTA of “Diphtheria and Tetanus Toxoids and Component Pertussis Vaccine Adsorbed” to CFDA 89
Oct 20, 2014: US FDA Accepts for Review a Biologics License Application for Merck and Sanofi Pasteur’s Investigational Pediatric Hexavalent Vaccine 89
Apr 01, 2014: Sanofi Pasteur Announces FDA Has Expanded Age Indication of Adacel Tdap Vaccine to Include Persons 10 Years of Age 90
Apr 22, 2013: Sanofi Obtains European Approval For Six-in-One Pediatric Vaccine Hexyon/Hexacima 91
Feb 22, 2013: Sanofi Pasteur Announces EMA’s CHMP Recommends Approval Of Hexyon/Hexacima Six-In-One Pediatric Vaccine 92
Oct 19, 2012: Sanofi Pasteur To Commercialize New 6-in-1 Paediatric Vaccine In European Markets 92
Jun 22, 2012: Sanofi Pasteur’s Hexaxim Receives Positive Opinion From European Medicines Agency 93
Mar 13, 2008: U.S. FDA Licenses DAPTACEL Vaccine for the Fifth Consecutive Dose in the Pediatric DTaP Immunization Series 94
Jul 25, 2005: Sanofi pasteur Begins Shipping ADACEL Vaccine in the U.S. for Combined Protection against Tetanus, Diphtheria, and Pertussis 95
Jun 13, 2005: U.S. FDA Licenses sanofi Pasteur’s ADACEL Vaccine for Combined Protection against Tetanus, Diphtheria and Pertussis 95
Jun 10, 2005: Society for Adolescent Medicine Statement on the FDA Licensure of Adacel Vaccine 96
Mar 18, 2005: FDA Advisory Panel Recommends Licensure of sanofi pasteur’s ADACEL Vaccine for Combined Protection against Tetanus, Diphtheria and Pertussis 96
Aug 11, 2004: Aventis Submits Application for FDA Licensure of ADACEL Vaccine for Prevention of Tetanus, Diphtheria and Pertussis in Adolescents and Adults. 97
May 14, 2002: Food and Drug Administration Approval of a Fifth Acellular Pertussis Vaccine for Use Among Infants and Young Children 98
Appendix 99
Methodology 99
Coverage 99
Secondary Research 99
Primary Research 99
Expert Panel Validation 99
Contact Us 99
Disclaimer 100

Get It Now @ https://www.wiseguyreports.com/checkout?currency=one_user-USD&report_id=693301

 

Contact US:

NORAH TRENT

Partner Relations & Marketing Manager

sales@wiseguyreports.com

Ph: +1-646-845-9349 (US)

Ph: +44 208 133 9349 (UK)          

Report abuse

Comments

Your Comments
Question   Razz  Sad   Evil  Exclaim  Smile  Redface  Biggrin  Surprised  Eek   Confused   Cool  LOL   Mad   Twisted  Rolleyes   Wink  Idea  Arrow  Neutral  Cry   Mr. Green

Top Stories
Recent Stories

Register

Newsletter

Email this story
Email this story

If you really want to ban this commenter, please write down the reason:

If you really want to disable all recommended stories, click on OK button. After that, you will be redirect to your options page.